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Abstract
Liver metastasis from breast cancer usually results in the development of systemic metastasis. We report
a breast cancer patient with an early isolated liver recurrence who survived more than 7 years with no
recurrence. She was treated with aggressive HER2-directed chemotherapy and hepatic metastasectomy.
Local hepatectomy with effective medical oncological therapy with curative intent is worth trying in
patients with breast cancer liver metastasis.
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Background
The liver is the primary site of recurrence in 12–15% of
breast cancer patients [1]. Under routine imaging
workup such as positive emission tomography (PET)
and computed tomography (CT), the incidence of an
isolated liver metastasis has been reported as approxi-
mately 0.9% among patients who underwent breast
cancer surgery [2]. Even in patients with an isolated liver
metastasis at the first presentation, breast cancer liver
metastasis (BCLM) is usually part of generalized meta-
static disease, resulting in the development of systemic
metastasis. If treated with chemotherapy, the median
survival of breast cancer patients with only liver metas-
tasis or with limited disease elsewhere is 19 to 26 months
[3]. For the select subset of patients presenting with
isolated BCLM, hepatic metastasectomy has been proposed
as a useful treatment associated with a good outcome [4].
However, the strategy of hepatic metastasectomy in BCLM
is still debatable. We present a patient who developed a
solitary BCLM as the first recurrence and yet achieved
long-term disease-free survival after aggressive human
epidermal growth factor receptor 2 (HER2)-directed
chemotherapy and hepatic metastasectomy.
Case presentation
A 56-year-old woman was referred to our hospital with
a 1-month history of a lump in her left breast. Physical
examination revealed a 4.0 × 3.0-cm tumor in the lower
outer quadrant of the left breast. Biopsy specimen by
core needle biopsy from the left breast lump showed an
invasive ductal carcinoma that was both estrogen recep-
tor (ER)- and progesterone receptor (PgR)-negative with
a HER2 of 3+ by immunohistochemistry assay. A PET/
CT scan showed uptake of 18F-fluorodeoxyglucose only
in the left breast tumor and the left axillary lymph
nodes, but not in distant organs. The patient was diag-
nosed with primary breast cancer (cT2N1M0 stage IIB
according to the Union for International Cancer Control
(UICC) classification).
She received preoperative chemotherapy consisting of
paclitaxel (80 mg/m2) weekly for 12 weeks, followed by
5-fluorouracil, epirubicin, and cyclophosphamide (FEC)
(500/100/500 mg/m2) four times every 3 weeks. Follow-
ing preoperative chemotherapy, physical examination
revealed only induration of the left breast. Preoperative
chest and abdominal CT scanning with contrast medium
showed no signs of distant metastasis.
The patient underwent a modified radical mastectomy
of the left breast. Pathological evaluation confirmed
residual invasive ductal carcinoma within the breast
tissue (ER- and PgR-negative, HER2 3+) and metastatic
carcinoma within three dissected axillary lymph nodes.
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Following surgery, the patient received weekly trastu-
zumab monotherapy (initially 4 mg/kg, followed by two
or more cycles of 2 mg/kg) as adjuvant treatment. Three
months after the start of trastuzumab, the patient’s
serum HER2 level had increased to 17.6 ng/ml (normal
range <15.2 ng/ml). Metastatic workup with PET/CT
scan and sonography of the liver revealed an isolated
liver metastasis (segment IV, 16 × 18 mm in diameter)
(Fig. 1). Weekly trastuzumab and vinorelbine ditartrate
(25 mg/m2, day 1, 8, every 3 weeks) were administered
as the first-line treatment, but the tumor did not re-
spond. Then, weekly trastuzumab and triweekly doce-
taxel (60 mg/m2) were administered as the second-line
treatment. However, 2 months later, the liver metastasis
had progressed. We modified the chemotherapeutic regi-
men to oral capecitabine (1650 mg/m2, day 1–14, every
21 days) along with trastuzumab and triweekly docetaxel
as the third-line treatment. After 4 cycles of this chemo-
therapy, CT scanning showed that the size of the liver
metastasis had decreased. However, soon after, progres-
sion of the remaining liver metastasis was anticipated
from her clinical course.
After adequate informed consent, the patient under-
went partial resection of the liver (R0) (Fig. 2). The
tumor was consistent with liver metastasis (7 × 9 mm)
from breast cancer and showed the same pathological
characteristics: ER- and PgR-negative, HER2 3+. After
liver metastasectomy, the patient was administered a
combined chemotherapy regimen of weekly trastuzumab
and oral capecitabine. Two months later, her cardiac
function had deteriorated as an adverse effect of the
chemotherapy. Although she has not been treated there-
after, no local recurrence or other distant metastases
have appeared for more than 7 years.
Discussion
The patient described here had favorable long-term
survival after diagnosis of liver metastasis, which may
demonstrate that a select group of patients with isolated
liver metastasis can benefit from aggressive systemic
HER2-directed chemotherapy and complete surgical re-
section, even without continuous chemotherapy.
Weichselbaum and Hellman proposed that a state of
oligometastasis may exist in which the metastases are
limited in number and site [5]. Good outcome has been
observed in patients treated with local therapy for oligo-
metastasis. Although local hepatectomy is possible for
solitary BCLM, many patients develop recurrent disease
[4]. In a study by Lermite et al., liver recurrences were
diagnosed at a mean interval of 15 months post-
hepatectomy and extrahepatic recurrences at 22 months
[6]. Ruiterkamp and Ernst found that in 13–56% of all
cases in their study, the first location of recurrence was
in the remaining liver [7]. It is not possible to predict
the subsequent clinical course of disease, or to deter-
mine whether the presence of limited liver metastasis
represents a true state of oligometastasis or a transi-
tional state to disseminated metastasis. In the present
case, early hepatic recurrence developed at 3 months
after mastectomy—during adjuvant trastuzumab thera-
py—fitting into the latter scenario. Achievement of only
local control of liver metastasis could rarely be “cura-
tive.” Co-administration of effective medical oncological
therapy may be needed for long-term survival.
In the literature, several independent factors have been
proposed that might influence the prognosis of breast
cancer patients after liver metastasectomy (Table 1). A
literature search was performed through the Medical
Literature Analysis and Retrieval System Online (MED-
LINE) database. Fisher et al. first reported in 1990 the
Fig. 1 Abdominal computed tomography. Postoperative abdominal
computed tomography revealed an ill-defined mass (white arrow),
16 × 18 mm in diameter, on liver segment IV
Fig. 2 Gross view of liver tumor. Gross view of liver tumor (white
arrowheads) shows a yellowish-white, elastic-hard solid component,
7 × 9 mm in diameter
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efficacy of the Adriamycin and cyclophosphamide (AC)
regimen, which today is one of the main prescribed
chemotherapy regimens for breast cancer [8]. Therefore,
we selected reports that were published after 1990. As a
general problem, most published studies are designed as
retrospective single-arm and single-center analyses, ana-
lyzing data of only small sample sizes that were collected
over periods of ≥10 years. Our literature search showed
that there is no clear consensus on selection criteria for
referral of patients for liver metastasectomy.
With this background, most authors have described
achievement of R0 (complete macroscopic and micro-
scopic) resection as the main prognostic factor for breast
cancer patients after liver metastasectomy [9, 10]. Two
selection criteria for patients to be accepted for curative
hepatic resection are, first, the absence of extrahepatic
disease (with the exception of isolated pulmonary and
bony metastases) and, second, the ability of the surgeon
to perform an R0 resection with a low risk of morbidity
[11]. Furthermore, solitary liver metastasis is a signi-
ficant prognostic factor [12–14]. Preoperative detailed
exploration using multislice CT, contrast-enhanced MRI,
or PET scan should be mandatory to minimize unneces-
sary surgery and maximize survival benefit.
The second prognostic factor for breast cancer pa-
tients after liver metastasectomy is a long interval (more
Table 1 Prognostic factors of overall survival in patients after liver metastasectomy from breast cancer. (only multivariate Cox
regression analyses)
Study Hoffman10 Abott15 Walsum12 Zegarac13 Dittmar16 Weinrich9 Vertriest14
Number 41 86 32 32 34 21 27
Duration 1999–2008 1997–2010 1991–2011 2006–2009 1997–2010 2001–2007 1996–2013
Median overall survival (months) 58 57 55 37 36 53 116
5-year overall survival (%) 48.4 37 28 33 78
Median disease-free survival (months) 34 14.2 11 22.5
5-year disease-free survival (%) 31 19 36
Characteristics of primary BC
ER status p = 0.009 p < 0.05
(pos) (pos)
Lymph node status p < 0.05
(neg)
Tumor size p < 0.05
(<3 cm)
Grading p = 0.0059
Stage p = 0.03
(Stages I–II)
Characteristics of LM and LM treatment
Age p = 0.004
(<50)
Period from BC to LM p = 0.0097 p < 0.05
(>24 months) (>24 months)
Number of LM p < 0.05 p < 0.01 p = 0.04
(1 vs >1) (1 vs >1) (1 vs >1)
HER2 status p = 0.010
(pos)
Absence of extrahepatic tumor p = 0.042
Response to preoperative chemotherapy p = 0.003
(good response)
Resection margins p = 0.0015
(R0 vs R1/2)
BC breast cancer, ER estrogen receptor, LM liver metastasis, HER2 human epidermal growth factor receptor 2, neg negative, pos positive, R0 complete microscopic
resection, R1 microscopic residual disease, R2 macroscopic residual hepatic or extrahepatic disease
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than 1 year) between diagnosis of breast cancer and
detection of liver metastasis [6, 7, 10, 13]. Several studies
have found that patients with ER- and/or PgR-positive
BCLM are good candidates for liver metastasectomy due
to favorable tumor biology and administration of hor-
mone therapy [13, 15]. Such characteristics of primary
breast cancer as small tumor size, node negativity, low
grade and early stage may also be associated with better
outcome after liver metastasectomy [9, 13, 14]. On the
other hand, patients with triple negative phenotype in
the primary breast cancer and/or liver metastases may
not benefit from liver metastasectomy due to aggressive
biological behavior and limited treatment strategies.
The third factor proposed as influencing the prognosis
of breast cancer patients after metastasectomy is re-
sponse to preoperative systemic therapy [15]. If systemic
therapy can eradicate microscopic metastatic tumor in
remnant liver and systemic organs, aggressive local ther-
apies to treat limited BCLM may translate into improved
survival. The response may also serve as a guide for
further postoperative therapy. On the other hand, the
patient who has not demonstrated disease regression or
stability with systemic chemotherapy may not be a candi-
date for liver metastasectomy. Overexpression of HER2 on
hepatic metastases may be correlated with improved sur-
vival [16, 17]. Pooled discordance proportion between pri-
mary and recurrent breast cancer was reported in 8% of
patients with HER2, 20% of patients with ER, and 33% of
patients with PgR by a meta-analysis [18]. Furthermore, it
is suggested that the mutation of the metastatic phenotype
is lower at earlier recurrence sites. Actually, no biological
change was demonstrated between primary and corre-
sponding asynchronous liver metastasis in the present
patient. Response-guided chemotherapy for liver metastasis
may also be effective in systemic micro-metastasis, contrib-
uting to long-term survival with no continuous chemother-
apy. Because of remarkable progress in the effectiveness of
HER2-directed therapy, the use of local therapy to treat
limited BCLM may expand further in patients with overex-
pression of HER2 on hepatic metastases [6].
Conclusions
Liver metastasectomy may offer a survival advantage
over systemic chemotherapy alone in select patients with
BCLM. However, independent prognostic factors pre-
dictive for survival are still not clearly defined. Further
studies are needed to identify a subgroup of patients
who may benefit from aggressive multidisciplinary treat-
ment including liver metastasectomy.
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